Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rock Creek Pharmaceuticals, a subsidiary of Star Scientific has announced the completion of human clinical trial showing that Anatabloc, the dietary supplement developed to provide anti-inflammatory support, lowers C-reactive protein (CRP) levels in subjects' blood.
Subscribe to our email newsletter
Rock Creek is reporting initial results from Phase 2 of the RCP-006 study titled ‘A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Efficacy of Anatabloc, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers, Followed by an Open-Label Extension Period.’
Phase 2 of the study was an open-label extension in which subjects were instructed to take two Anatabloc tablets three times per day for two weeks.
The data analysis examined the CRP and anatabine levels in the subjects’ blood, first to establish a baseline, and then to assess levels with Anatabloc dosing.
Phase 1 of the study was a one-day trial to assess whether Anatabloc was as good as CigRx, the company’s other dietary supplement, in reducing the urge to smoke, and results showed that CigRx and Anatabloc were equally effective.